Adial Pharmaceuticals begins dosing patients in a 6-month pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinkers to optimize Phase 3 trial design.
Adial Pharmaceuticals (NASDAQ: ADIL) has begun dosing patients in a pharmacokinetics study of AD04 for Alcohol Use Disorder in heavy drinkers. The 6-month study aims to optimize the design elements for the upcoming Phase 3 clinical trial, satisfy FDA guidance, and inform discussions for potential partnerships. The results could support an application for AD04 approval under the 505(b)(2) regulatory pathway.
June 05, 2024
4 Articles